[Risedronate].
Risedronate (RSD) containing nitrogen, the third generation of bisphosphonate, has a powerful antiresorptive activity, without a stronger inhibition of mineralization. RSD is available for the treatment of osteoporosis. In Japanese the effective dose is 2.5 mg given orally daily, while in Caucasians it is 5 mg. This difference of dose suggests that RSD may be absorbed more efficiently in Japanese than in Caucasians. RSD administered orally at 2.5 mg per day for 48 weeks induced a 5% increase of bone mineral density in the lumbar spines in osteoporotic women. RSD, 5 mg daily, decreases vertebral and non-vertebral, especially hip fractures in elderly osteoporotic women. Thus, RSD is an important agent for the treatment of osteoporosis.